FY2024 Earnings Forecast for Indivior PLC (NASDAQ:INDV) Issued By Northland Capmk

Indivior PLC (NASDAQ:INDV) – Analysts at Northland Capmk dropped their FY2024 earnings per share (EPS) estimates for shares of Indivior in a research note issued to investors on Tuesday, September 17th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $1.58 for the year, down from their previous forecast of $1.60. The consensus estimate for Indivior’s current full-year earnings is $1.70 per share.

Several other analysts have also recently weighed in on the stock. Craig Hallum decreased their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Piper Sandler reissued an “overweight” rating and issued a $22.00 target price on shares of Indivior in a report on Friday, September 13th.

Indivior Trading Down 0.9 %

Shares of Indivior stock opened at $9.68 on Thursday. Indivior has a 12-month low of $9.14 and a 12-month high of $23.22. The stock has a market capitalization of $1.33 billion, a P/E ratio of 968.00 and a beta of 0.68. The company has a 50-day simple moving average of $11.72 and a 200 day simple moving average of $16.00. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The firm had revenue of $299.00 million during the quarter, compared to analyst estimates of $285.90 million.

Hedge Funds Weigh In On Indivior

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new stake in shares of Indivior during the second quarter worth $188,000. VELA Investment Management LLC bought a new stake in Indivior during the 2nd quarter worth about $235,000. XTX Topco Ltd acquired a new position in Indivior during the 2nd quarter valued at about $249,000. Chilton Investment Co. Inc. bought a new position in shares of Indivior in the 4th quarter valued at about $263,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Indivior in the 4th quarter valued at about $368,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.